These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32001301)

  • 1. Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver.
    Canivet CM; Bonnafous S; Rousseau D; Leclere PS; Lacas-Gervais S; Patouraux S; Sans A; Luci C; Bailly-Maitre B; Iannelli A; Tran A; Anty R; Gual P
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165705. PubMed ID: 32001301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAD
    Li DJ; Sun SJ; Fu JT; Ouyang SX; Zhao QJ; Su L; Ji QX; Sun DY; Zhu JH; Zhang GY; Ma JW; Lan XT; Zhao Y; Tong J; Li GQ; Shen FM; Wang P
    Theranostics; 2021; 11(9):4381-4402. PubMed ID: 33754067
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.
    Metwally M; Bayoumi A; Romero-Gomez M; Thabet K; John M; Adams LA; Huo X; Aller R; García-Monzón C; Teresa Arias-Loste M; Bugianesi E; Miele L; Gallego-Durán R; Fischer J; Berg T; Liddle C; Qiao L; George J; Eslam M
    J Hepatol; 2019 Mar; 70(3):494-500. PubMed ID: 30389552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes.
    Liu TY; Shi CX; Gao R; Sun HJ; Xiong XQ; Ding L; Chen Q; Li YH; Wang JJ; Kang YM; Zhu GQ
    Clin Sci (Lond); 2015 Nov; 129(10):839-50. PubMed ID: 26201094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FNDC5 Alleviates Hepatosteatosis by Restoring AMPK/mTOR-Mediated Autophagy, Fatty Acid Oxidation, and Lipogenesis in Mice.
    Liu TY; Xiong XQ; Ren XS; Zhao MX; Shi CX; Wang JJ; Zhou YB; Zhang F; Han Y; Gao XY; Chen Q; Li YH; Kang YM; Zhu GQ
    Diabetes; 2016 Nov; 65(11):3262-3275. PubMed ID: 27504012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise.
    Huh JY; Panagiotou G; Mougios V; Brinkoetter M; Vamvini MT; Schneider BE; Mantzoros CS
    Metabolism; 2012 Dec; 61(12):1725-38. PubMed ID: 23018146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ghrelin Reduces TNF-α-Induced Human Hepatocyte Apoptosis, Autophagy, and Pyroptosis: Role in Obesity-Associated NAFLD.
    Ezquerro S; Mocha F; Frühbeck G; Guzmán-Ruiz R; Valentí V; Mugueta C; Becerril S; Catalán V; Gómez-Ambrosi J; Silva C; Salvador J; Colina I; Malagón MM; Rodríguez A
    J Clin Endocrinol Metab; 2019 Jan; 104(1):21-37. PubMed ID: 30137403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
    Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice.
    Xia H; Zhu X; Zhang X; Jiang H; Li B; Wang Z; Li D; Jin Y
    Biomed Pharmacother; 2019 Oct; 118():109287. PubMed ID: 31401392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
    Li T; Huang X; Yue Z; Meng L; Hu Y
    Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2.
    Zhu W; Sahar NE; Javaid HMA; Pak ES; Liang G; Wang Y; Ha H; Huh JY
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High fat diet-induced oxidative stress blocks hepatocyte nuclear factor 4α and leads to hepatic steatosis in mice.
    Yu D; Chen G; Pan M; Zhang J; He W; Liu Y; Nian X; Sheng L; Xu B
    J Cell Physiol; 2018 Jun; 233(6):4770-4782. PubMed ID: 29150932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.